Trevi Therapeutics, Inc. Common Stock (TRVI) is a publicly traded Healthcare sector company. As of May 21, 2026, TRVI trades at $13.88 with a market cap of $1.91B and a P/E ratio of -29.24. TRVI moved +4.83% today. Year to date, TRVI is +22.18%; over the trailing twelve months it is +114.53%. Its 52-week range spans $2.36 to $16.12. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces TRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TRVI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRVI recently traded at $13.88. Market cap is $1.91B. P/E ratio is -29.24. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $13.88 |
| Market Cap | $1.91B |
| P/E Ratio | -29.24 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.12 |
| 52-Week Low | $2.36 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-47.91M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $0 | $-47.91M | $-0.47 |
| 2023 | $0 | $-29.07M | $-0.29 |
| 2022 | $0 | $-29.15M | $-0.45 |
| 2021 | $0 | $-33.94M | $0.00 |
8 analysts cover TRVI: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.